TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic, uncomplicated Plasmodium falciparum infection~* Positive malaria microscopy or malaria RDT (pLDH)~* Age: 18-50 years~* Provide written informed consent~* Agree to be able to travel to clinic on days: 1, 2, 7, 10, 14, 21, and 28~Exclusion Criteria:~* Signs or symptoms of severe malaria~* Unable to provide written informed consent~* For women: pregnancy or lactation~* Hypersensitivity to ivermectin or DP~* QTc \>460 ms on ECG~* Body Mass Index (BMI) below 16 or above 32 kg/m2~* Haemoglobin concentration below 9 g/dL~* Taken ivermectin in the last month~* Taken dihydroartemisinin-piperaquine in the last 12 weeks~* Loa loa as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan~* History and/or symptoms indicating chronic illness~* Current use of tuberculosis or anti-retroviral medication~* Previously enrolled in the same study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
- ivermectin 300 mcg/kg (Type: EXPERIMENTAL): Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
- ivermectin 600 mcg/kg (Type: EXPERIMENTAL): Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to a rehabilitation hospital with primary diagnosis of ischemic stroke (cardiovascular accident)~* Stroke was within 30 days of being admitted~* Medically stable~* Presence of memory and/or attentional impairments and evidence that these impairments were not present or were less severe prior to the stroke (assessed via interview with family)~* Approval by individual's attending physician at the rehabilitation hospital~Exclusion Criteria:~* Aphasia or cognitive (or behavioral) impairments severe enough to prevent valid neuropsychiatric assessment~* Currently experiencing a major depressive episode (unless treated and in partial remission, assessed using the Primary Care Evaluation of Mental Disorders)~* Current psychosis or mania~* History of substance or alcohol abuse or dependence within three months of study entry~* Currently taking a cholinomimetic drug~* Medical condition with known sensitivity to donepezil (e.g., slower than normal heart rate, supraventricular cardiac conduction defects, severe asthma or obstructive pulmonary disease, active upper gastrointestinal bleed, or gastric/duodenal ulcer if not on acid-blocking agent)~* Informed that taking donepezil is medically inadvisable~* Current use of any anticholinergic medication (e.g., for bladder spasm)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Galantamine (Type: EXPERIMENTAL): Galantamine for 12 weeks
- Donepezil (Type: EXPERIMENTAL): Donepezil for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COlchicine in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients awaiting elective cardiac surgery (CABG and/or AVR (aortic valve replacement), who are willing and able to give informed consent for participation in the study and who are in sinus rhythm and not taking any antiarrhythmic medication, except beta-adrenergic blocking agents, at the time before surgery.~Exclusion Criteria:~* History of persistent or long-term atrial fibrillation/atrial flutter~* Congenital heart disease, except the bicuspid AV~* Frequent VE/SVE, AV block 2-3 degrees~* Use of corticosteroids during the last month~* Taking any antiarrhythmic drugs, except beta-blockers, within the last 1 month~* Prior open heart surgery~* Moderate to severe renal failure (creatinine clearance \< 50 ml / min)~* History of obstructive hepato-biliary disease or other serious hepatic disease~* Significant mitral valve disease (moderate or severe mitral regurgitation-eg. \> grade II and/or mitral stenosis \& mitral annular calcification).~* Patient participation in another clinical trial

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: EXPERIMENTAL): Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)
- Placebo (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who weigh ≥15 kg without shoes a the Screening Visit~* Subjects with confirmed diagnosis of CF at the Screening Visit.~* Subjects who are homozygous for the F508del CFTR mutation~* Subjects with ppFEV1 of ≥70 percentage points adjusted for age, sex, and height~* Subjects with a screening LCI2.5 result greater than or equal to 7.5~Exclusion Criteria:~* History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.~* Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject~* Clinically significant abnormalities in hemoglobin, liver function, or renal function at the Screening Visit.~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1~* History of solid organ or hematological transplantation at the Screening Visit

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- LUM/IVA (Type: EXPERIMENTAL): Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo q12h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males or females~2. Age 18-50 years (incl.)~3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)~4. Subjects must be able to understand and comply with study requirements~Exclusion criteria:~Any deviation from healthy condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- High dose, fasted (Type: EXPERIMENTAL): 1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
- High dose, fed (Type: EXPERIMENTAL): 1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
- Low dose, fasted (Type: EXPERIMENTAL): 2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: older than 19~* A patient with stable non-segmental vitiligo~* A patient with symmetrical vitiligo lesions on face~* A patient with the willingness to comply with the study protocol during the study period and capable of complying with it.~* A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages.~Exclusion Criteria:~* Age: lower than 20~* A pregnant or lactating patient~* A patient with active or spreading vitiligo~* A patient who cannot understand the study or who does not sign the informed consent~* Women of childbearing potential not using an effective method of contraception properly

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tretinoin 0.05% cream group (Type: EXPERIMENTAL): Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
- Placebo (Type: PLACEBO_COMPARATOR): PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Assessment of Glutamatergic Target Engagement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55~* Negative Urine Toxicology~* No present or past psychiatric conditions (including substance abuse or dependence, with the exception of nicotine dependence)~* No family history of schizophrenia in a first-degree relative~Exclusion Criteria:~* Any current DSM IV Axis I disorder and/or past substance abuse of dependence (nicotine dependence is allowed)~* Any current use of amphetamines, opiates, cocaine, sedative-hypnotics, or cannabis~* Current (i.e., within the last 3 months) treatment with any psychotropic medications~* Pregnancy, lactation, or lack of use of effective birth control~* Presence of positive history of significant medical or neurological illness (including any history of seizure), including high blood pressure (SBP \>140, DBP \>90), low blood pressure (SBP \<100, DBP \<60), orthostatic BP change\>20% (1/3 SBP + 2/3 DBP) or cardiac illness or resting heart rate \>100 or \<50~* History of significant violent behavior~* History of recreational ketamine use, recreational PCP use, or an adverse reaction to ketamine. Subjects who have participated prior research ketamine studies will be eligible providing they have participated in no more than 5 previous research ketamine infusions. Subjects can have infusions not more frequently than biweekly and not more than 1/month on average, therefore subjects entering the study will need to wait 1 month if they had a single infusion and 6 weeks if they have had two closely spaced infusions.~* Contraindication to MRI scanning, including metal implants or claustrophobia. Metal implants, pacemaker, other metal (e.g. shrapnel or surgical prostheses) or paramagnetic objects contained within the body which may present a risk to the subject or interfere with the MR scan, as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by neuroradiologists: Guide to MR procedures and metallic objects, F.G. Shellock, Lippincott Williams and Wilkins NY 2001~* Color Blindness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ketamine (Type: EXPERIMENTAL): IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group will receive normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19-45 years of age, male or female~* presumed diagnosis of urogenital C. trachomatis infection~* use condoms during sexual activity during study (enrollment thru day 28)~Exclusion Criteria:~* Clinical diagnosis pelvic inflammatory disease or epididymitis at baseline~* Diagnosis of N. gonorrhoea~* HIV infection~* Active Hepatitis B or C infection~* Prior hysterectomy (partial or total)~* Treatment with antimicrobial therapy with known activity against urogenital C. trachomatis within 28 days of enrollment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Doxycycline Hyclate 200 mg tablet (Type: EXPERIMENTAL): Once daily
- Vibramycin 100 mg capsule (Type: ACTIVE_COMPARATOR): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects older than 35 years old will be considered~* Gestational diabetes mellitus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-lactating, non-pregnant female subjects who are 40 years or older at the time of initial dosing~  --Physical status within normal limits for age and consistent with observations at Screening~* Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed~Exclusion Criteria:~* History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors (PPIs)~* History of hypersensitivity, allergy or intolerance to aspirin or any NSAID and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps~* History of hypersensitivity or intolerance to clopidogrel~* History of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies~* History of malignancy, treated or untreated, within the past five years, with the exception of successfully treated basal cell or squamous cell carcinoma of -Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the Investigator's opinion, would endanger a subject if he/she were to participate in the study~* Presence of an uncontrolled acute, or a chronic medical illness, e.g., GI disorder, diabetes, hypertension, thyroid disorder, bleeding disorder, infection, which in the Investigator's opinion would endanger a subject if he/she were to participate in the study or interfere with the objective of this study~* Schizophrenia or bipolar disorder~* GI disorder or surgery leading to impaired drug absorption~* \< 70% platelet aggregation at Screening~* Donation of blood or plasma within 4 weeks of the study~* PPI use or any enzyme inducing/inhibiting agents within 4 weeks prior to dosing~* Taking any antiplatelet drug within 2 weeks of the screening visit or during the study, or more than two 325 mg doses of aspirin or more than 2 doses of any other NSAIDs within 14 days prior to the screening visit

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Clopidogrel (Plavix®) and PA32540 (Type: EXPERIMENTAL): PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
- EC aspirin, EC omeprazole, Clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 5 to 12 years old~* pathogenic deletions or mutations of the SHANK3 gene~* stable medication regimens for at least three months prior to enrollment~Exclusion Criteria:~* closed epiphyses~* active or suspected neoplasia~* intracranial hypertension~* hepatic insufficiency~* renal insufficiency~* cardiomegaly / valvulopathy~* history of allergy to IGF-1 or any component of the formulation (mecasermin)~* history of extreme prematurity (\<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral hemorrhage, prolonged hypoxia, prolonged hypoglycemia~* patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Insulin-Like Growth Factor-1 (IGF-1) (Type: EXPERIMENTAL): Injection
- Normal saline (Type: PLACEBO_COMPARATOR): Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>14 years~* Weight \> 40 kg~* Primary renal allograft: cadaveric or mismatched living donor~* Negative standard cross match for T-cells~* Women of childbearing potential will be required to have a negative qualitative serum pregnancy test and agree to use an adequate method of contraception throughout the study period and for 3 months after discontinuation of study medication (3yrs, 3 mos.)~* Signed and dated informed consent (Parent or legal guardian must provide written consent for patients \<18 years of age)~Exclusion Criteria:~* Evidence of systemic infection~* History of malignancy within 10 years (with the exception of localized skin cancer)~* Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the 12-month treatment phase~* Concurrent use of astemizole, pimozide, cisapride, terfenadine, or ketoconazole~* Known hypersensitivity to sirolimus and its derivatives~* Patients with a screening/baseline (or within 96 hours of transplant)~  * total white blood cell count \< 4000/mm3;~ * platelet count \< 100,000/mm3;~ * fasting triglycerides \> 400 mg/dl (\> 4.6 mmol/L);~ * fasting total cholesterol \> 300 mg/dl (\> 7.8 mmol/L);~ * fasting HDL-cholesterol \< 30 mg/dl;~ * fasting LDL-cholesterol \> 200mg/dl

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Tacrolimus/Sirolimus
- B (Type: EXPERIMENTAL): Tacrolimus/MMF
- C (Type: EXPERIMENTAL): Neoral/Sirolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete